Stockscreener 앱 받기
0.00
100.00%
-3.65
시간 외 거래:
3.66
3.66
+
전일 마감가:
$3.65
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$381.02M
수익:
$234.04M
순이익/손실:
$-323.92M
주가수익비율:
0.00
EPS:
-3.8
순현금흐름:
$-223.46M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$6.65
Revance Therapeutics Inc Stock (RVNC) Company Profile
명칭
Revance Therapeutics Inc
전화
(615) 724-7755
주소
1222 DEMONBREUN STREET, NASHVILLE, CA
RVNC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVNC
Revance Therapeutics Inc
|
0.00 | 381.02M | 234.04M | -323.92M | -223.46M | -3.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-29 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-01-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-08-16 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-22 | 개시 | Goldman | Buy |
| 2021-10-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-15 | 재확인 | Needham | Buy |
| 2020-08-11 | 재개 | Mizuho | Buy |
| 2020-03-23 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-12-02 | 개시 | Goldman | Buy |
| 2019-10-30 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-02-15 | 개시 | Wells Fargo | Market Perform |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2019-01-29 | 개시 | Stifel | Buy |
| 2018-11-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2018-09-17 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-04-20 | 재확인 | Mizuho | Buy |
| 2018-03-27 | 개시 | Needham | Buy |
| 2018-03-05 | 개시 | Goldman | Buy |
| 2018-01-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2017-12-06 | 개시 | Guggenheim | Buy |
| 2017-12-06 | 재확인 | Mizuho | Buy |
| 2017-11-27 | 개시 | Barclays | Overweight |
| 2017-11-17 | 개시 | Mizuho | Buy |
| 2017-08-22 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Revance Therapeutics Inc 주식(RVNC)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Raises Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Investigation announced for Long-Term Investors in Revance - openPR.com
Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance - insights.citeline.com
JPMorgan Chase & Co. Sells 2,335,359 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics (NASDAQ:RVNC) Earns Hold Rating from Analysts at StockNews.com - Defense World
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by Vanguard Group Inc. - Defense World
Corebridge Financial Inc. Reduces Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Wellington Management Group LLP Trims Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Norges Bank Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
KLP Kapitalforvaltning AS Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Commonwealth Equity Services LLC Cuts Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Average Recommendation of “Hold” from Analysts - Defense World
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - Defense World
BIOJUVE® Honoured as Best Cosmetics of the Year at AMWC 2025 in Monaco - The Malaysian Reserve
Public market insider buying at Prime Mining (PRYM) - The Globe and Mail
RVNC INVESTIGATION: Hagens Berman Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm’s Attorneys Now, Firm Investigating Possible Securities Law Violations - ACCESS Newswire
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bay Area drug veteran heads New Zealand company's oral ketamine spinoff targeting depression - The Business Journals
Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Revance Therapeutics, Inc. a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022RVNC - ACCESS Newswire
Crown Laboratories rebrands as Revance following acquisition - MSN
Johnson City-based Crown Labs now operating as ‘Revance’ - WJHL
Crown Laboratories Now Operates Under the Name Revance - PR Newswire
Charles Schwab Investment Management Inc. Grows Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Purchased by Charles Schwab Investment Management Inc. - The AM Reporter
Revance Therapeutics, Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information - ACCESS Newswire
Bank of New York Mellon Corp Sells 18,519 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important February 8 Deadline in Securities Class Action – RVNC - Business Wire
Lost Money on Revance Therapeutics, Inc. (RVNC)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm - Louisiana First News
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $8.39 Average Price Target from Brokerages - Defense World
Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated by Analysts at StockNews.com - Defense World
Major Catalyst Alert: Dermata's Phase 3 Acne Treatment Results Coming in Weeks - StockTitan
Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com - Defense World
Rhumbline Advisers Boosts Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
ForexTV | Small Business Resources - ForexTV.com
REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Contact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC) - Stockhouse Publishing
Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025RVNC - ACCESS Newswire
Investors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class ActionRVNC - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
RVNC DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, - GlobeNewswire
Deadline Soon: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire
Revance Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
2025-03-03 | Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. (RVNC) of a Class Action Lawsuit and an Upcoming Deadline | Press Release - Stockhouse Publishing
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact The Gross Law Firm about pending Class ActionRVNC - PR Newswire
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
2025-03-02 | Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class ActionContact Levi & Korsinsky to Learn More | Press Release - Stockhouse Publishing
Revance Therapeutics Inc (RVNC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):